Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.42 |
| ▸ | DRD2 | P14416 | 8/20 | 0.42 |
| ▸ | DRD3 | P35462 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577640 | 0.96 | HTR4 (0.43) | DRD3ALDH1A1HTR4CCR3NPC1 | |
| SCHEMBL5577587 | 0.88 | MT-CO2 (0.45) | DRD4DRD2DRD3HTR4RAB9A | |
| SCHEMBL5577605 | 0.86 | LMNA (0.45) | DRD4DRD2DRD3HTR4CCR3 | |
| SCHEMBL5577408 | 0.85 | GAA (0.51) | ALDH1A1POLBGAAACKR3 | |
| SCHEMBL5577384 | 0.85 | ALDH1A1 (0.41) | DRD4DRD2DRD3ALDH1A1POLB | |
| SCHEMBL5577486 | 0.84 | DRD2 (0.47) | DRD4DRD2DRD3ALDH1A1POLB | |
| SCHEMBL5577431 | 0.84 | MT-CO2 (0.46) | DRD3ALDH1A1HTR4SIGMAR1ACKR3 | |
| SCHEMBL5577778 | 0.84 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL5577426 | 0.84 | PDE5A (0.41) | DRD4DRD2DRD3ALDH1A1POLB | |
| SCHEMBL5715680 | 0.83 | LMNA (0.45) | DRD4DRD2DRD3ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | DRD4 4092/4885DRD2 4468/4885DRD3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.